The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.La présente invention concerne la polythérapie d'un anticorps anti-CD20 afucosylé et d'un inhibiteur de mTOR pour le traitement du cancer, notamment la polythérapie de cancers exprimant CD20 par un anticorps B-Ly1 humanisé afucosylé et par un inhibiteur de mTOR tel que Temsirolimus ou Everolimus.